Author:
Julius Ulrich,Tselmin Sergey
Publisher
Springer International Publishing
Reference79 articles.
1. Arai K, Orsoni A, Mallat Z, Tedgui A, Witztum JL, Bruckert E, et al. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res. 2012;53(8):1670–8. https://doi.org/10.1194/jlr.P027235.
2. Arnold M, Schweizer J, Nakas CT, Schutz V, Westphal LP, Inauen C, et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. Eur Heart J. 2021;42(22):2186–96. https://doi.org/10.1093/eurheartj/ehab081.
3. Bigazzi F, Sbrana F, Berretti D, Maria Grazia Z, Zambon S, Fabris A, et al. Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. Transfus Apher Sci. 2018;57(5):661–4. https://doi.org/10.1016/j.transci.2018.07.015.
4. Boffa MB, Stranges S, Klar N, Moriarty PM, Watts GF, Koschinsky ML. Lipoprotein(a) and secondary prevention of atherothrombotic events: a critical appraisal. J Clin Lipidol. 2018;12(6):1358–66. https://doi.org/10.1016/j.jacl.2018.08.012.
5. Bundesministerium für Gesundheit. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung: Apherese bei isolierter Lp(a)-Erhöhung. BAnz. 2008;138:3321.